![]() |
|
|
2 Adrenergic Receptor
Department of Pharmacology, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece (G.L., M.P); Center for Molecular Recognition (W.C.C., J.A.J.) and Departments of Psychiatry and Pharmacology (J.A.J.), College of Physicians & Surgeons, Columbia University, New York, New York; and the New York State Psychiatric Institute, New York, New York (J.A.J.)
The structural basis of ligand affinity can be approached by studying the interactions between a drug and receptor residues; the basis for efficacy is more complex and must involve activation-associated conformational changes. We have used wild-type (WT), a constitutively active mutant (CAM), and a "constitutively inactive" mutant
2 adrenergic receptor (
2AR) to investigate changes in the binding site that accompany binding and activation. The active state (R*) probably involves repositioning of at least some of the agonist-contact residues, thereby optimizing their interactions with agonist and resulting in a higher affinity for agonist. A comparison of the binding affinities of a series of phenethylamine derivatives for WT revealed a remarkable synergism between the various functional groups present in epinephrine. Binding affinity was essentially unchanged with addition of
-OH, N-CH3, or catechol OHs to phenethylamine. In contrast, when each of these same groups was added to the appropriate compound, already containing the other two groups, to make epinephrine, the increase in affinity was quite large (60- to 120-fold). An initial interaction between two or more contacts may stabilize an intermediate conformation of
2AR, R', either by altering amino acid side chain rotamer conformations or by a more global conformational change involving the repositioning of transmembrane segments. The pattern of these effects was different in the CAM in that fewer interactions were required to observe the synergistic effect, consistent with the hypothesis that the CAM mutation enriches the proportion of receptors in R* or in R' from which R* is more readily assumed.
Address correspondence to: Dr. Jonathan A. Javitch, Center for Molecular Recognition, Columbia University, P&S 11-401, 630 West 168th Street, New York, NY 10032. E-mail: jaj2{at}columbia.edu
This article has been cited by other articles:
![]() |
B. Holst, J. Mokrosinski, M. Lang, E. Brandt, R. Nygaard, T. M. Frimurer, A. G. Beck-Sickinger, and T. W. Schwartz Identification of an Efficacy Switch Region in the Ghrelin Receptor Responsible for Interchange between Agonism and Inverse Agonism J. Biol. Chem., May 25, 2007; 282(21): 15799 - 15811. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Rosenkilde, M. B. Andersen, R. Nygaard, T. M. Frimurer, and T. W. Schwartz Activation of the CXCR3 Chemokine Receptor through Anchoring of a Small Molecule Chelator Ligand between TM-III, -IV, and -VI Mol. Pharmacol., March 1, 2007; 71(3): 930 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mamputha, Z.-l. Lu, R. W. Roeske, R. P. Millar, A. A. Katz, and C. A. Flanagan Conserved Amino Acid Residues that Are Important for Ligand Binding in the Type I Gonadotropin-Releasing Hormone (GnRH) Receptor Are Required for High Potency of GnRH II at the Type II GnRH Receptor Mol. Endocrinol., January 1, 2007; 21(1): 281 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Violin, X.-R. Ren, and R. J. Lefkowitz G-protein-coupled Receptor Kinase Specificity for beta-Arrestin Recruitment to the beta2-Adrenergic Receptor Revealed by Fluorescence Resonance Energy Transfer J. Biol. Chem., July 21, 2006; 281(29): 20577 - 20588. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Elling, T. M. Frimurer, L.-O. Gerlach, R. Jorgensen, B. Holst, and T. W. Schwartz Metal Ion Site Engineering Indicates a Global Toggle Switch Model for Seven-transmembrane Receptor Activation J. Biol. Chem., June 23, 2006; 281(25): 17337 - 17346. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Engel, S. Neumann, N. Kaur, V. Monga, R. Jain, J. Northup, and M. C. Gershengorn Low Affinity Analogs of Thyrotropin-releasing Hormone Are Super-agonists J. Biol. Chem., May 12, 2006; 281(19): 13103 - 13109. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Spijker, N. Vaidehi, P. L. Freddolino, P. A. J. Hilbers, and W. A. Goddard III Dynamic behavior of fully solvated beta2-adrenergic receptor, embedded in the membrane with bound agonist or antagonist PNAS, March 28, 2006; 103(13): 4882 - 4887. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ambrosio, P. Molinari, F. Fanelli, Y. Chuman, M. Sbraccia, O. Ugur, and T. Costa Different Structural Requirements for the Constitutive and the Agonist-induced Activities of the {beta}2-Adrenergic Receptor J. Biol. Chem., June 24, 2005; 280(25): 23464 - 23474. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Swaminath, X. Deupi, T. W. Lee, W. Zhu, F. S. Thian, T. S. Kobilka, and B. Kobilka Probing the {beta}2 Adrenoceptor Binding Site with Catechol Reveals Differences in Binding and Activation by Agonists and Partial Agonists J. Biol. Chem., June 10, 2005; 280(23): 22165 - 22171. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. P. Clarke What's for Lunch at the Conformational Cafeteria? Mol. Pharmacol., June 1, 2005; 67(6): 1819 - 1821. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Urizar, S. Claeysen, X. Deupi, C. Govaerts, S. Costagliola, G. Vassart, and L. Pardo An Activation Switch in the Rhodopsin Family of G Protein-coupled Receptors: THE THYROTROPIN RECEPTOR J. Biol. Chem., April 29, 2005; 280(17): 17135 - 17141. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tan, Z. Liu, R. Wang, Z. Y. Huang, A. C. Chen, M. Gurevitz, and K. Dong Identification of Amino Acid Residues in the Insect Sodium Channel Critical for Pyrethroid Binding Mol. Pharmacol., February 1, 2005; 67(2): 513 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Limbird The Receptor Concept: A Continuing Evolution Mol. Interv., December 1, 2004; 4(6): 326 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kobilka Agonist Binding: A Multistep Process Mol. Pharmacol., May 1, 2004; 65(5): 1060 - 1062. [Full Text] |
||||